US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
EP0627930A4
(en)
|
1992-07-13 |
1997-08-20 |
Kenneth E Sherman |
COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
|
US6107027A
(en)
|
1994-12-14 |
2000-08-22 |
University Of Washington |
Ribozymes for treating hepatitis C
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
US6387365B1
(en)
|
1995-05-19 |
2002-05-14 |
Schering Corporation |
Combination therapy for chronic hepatitis C infection
|
US5980884A
(en)
|
1996-02-05 |
1999-11-09 |
Amgen, Inc. |
Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
|
GB9605293D0
(en)
|
1996-03-13 |
1996-05-15 |
Glaxo Group Ltd |
Medicaments
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
AU5157998A
(en)
|
1996-11-01 |
1998-05-29 |
Thomas Najarian |
Methods and compositions for treatment of hepatitis c infection
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
US6103706A
(en)
|
1997-04-29 |
2000-08-15 |
New York Blood Center, Inc. |
Methods for treating viral infections
|
US6010890A
(en)
|
1997-04-29 |
2000-01-04 |
New York Blood Center, Inc. |
Method for viral inactivation and compositions for use in same
|
US6143752A
(en)
|
1997-08-01 |
2000-11-07 |
Oren; Ran |
Method for preventing or arresting liver damage in humans
|
DK1136075T3
(da)
|
1997-09-21 |
2003-04-28 |
Schering Corp |
Kombinationsterapi til udryddelse aff detekterbart HCV-RNA i patienter med kronisk hepatitis C infektion
|
JP3838034B2
(ja)
|
1997-10-13 |
2006-10-25 |
大塚製薬株式会社 |
C型肝炎治療効果の改善剤及びその応用
|
FR2771637B1
(fr)
|
1997-12-01 |
2003-10-24 |
Hutchinson |
Utilisation d'un halogenure de dialkyldialkylammonium par voie parenterale dans les infections bacteriennes et virales
|
WO1999029321A1
(en)
|
1997-12-11 |
1999-06-17 |
The Chancellor, Masters And Scholars Of The University Of Oxford |
Inhibition of membrane-associated viral replication
|
AU1703799A
(en)
|
1997-12-17 |
1999-07-05 |
Cornell Research Foundation Inc. |
Cyclooxygenase-2 inhibition
|
US7462605B2
(en)
|
1998-01-23 |
2008-12-09 |
Celmed Oncology (Usa), Inc. |
Phosphoramidate compounds and methods of use
|
WO1999049873A1
(en)
|
1998-03-27 |
1999-10-07 |
Regents Of The University Of Minnesota |
Nucleosides with antiviral and anticancer activity
|
JP2000007578A
(ja)
|
1998-06-24 |
2000-01-11 |
Hiroaki Okushin |
C型肝炎ウイルスの陰性化のための投薬システム
|
CN1218958C
(zh)
|
1998-07-01 |
2005-09-14 |
德比奥药物股份有限公司 |
活性范围改善的环孢菌素
|
RU2158604C2
(ru)
|
1998-07-03 |
2000-11-10 |
Толоконская Наталья Петровна |
Способ лечения вирусного гепатита c
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
RU2001113268A
(ru)
|
1998-10-16 |
2003-09-27 |
Шеринг Корпорейшн (US) |
Сочетанная терапия рибавирином и интерфероном α для удаления определяемой рнк вируса гепатита с у пациентов с хроническим гепатитом с
|
US6403564B1
(en)
|
1998-10-16 |
2002-06-11 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
US20080275005A1
(en)
|
1998-11-25 |
2008-11-06 |
Murphy Michael P |
Mitochondrially targeted antioxidants
|
WO2000037097A1
(en)
|
1998-12-18 |
2000-06-29 |
Schering Corporation |
Ribavirin-interferon alfa induction hcv combination therapy
|
US6824768B2
(en)
|
1998-12-18 |
2004-11-30 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction HCV combination therapy
|
AU2157000A
(en)
|
1998-12-18 |
2000-07-12 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
JP2000212099A
(ja)
|
1999-01-19 |
2000-08-02 |
Mochida Pharmaceut Co Ltd |
ウイルス性肝炎治療剤
|
DE60017243T2
(de)
|
1999-02-13 |
2005-12-08 |
Purepulse Technologies, Inc., San Diego |
Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
|
US6589570B1
(en)
|
1999-04-12 |
2003-07-08 |
University Of Madras |
Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation
|
US6849254B1
(en)
|
1999-04-19 |
2005-02-01 |
Schering Corporation |
HCV combination therapy
|
MXPA02000763A
(es)
|
1999-07-22 |
2002-08-12 |
Newbiotics Inc |
Activacion terapeutica catalizada por enzima.
|
BR0013252A
(pt)
|
1999-08-13 |
2002-04-16 |
Hoffmann La Roche |
Micofenolato mofetila em associação com peg-ifn-alfa
|
US20050245502A1
(en)
|
1999-08-23 |
2005-11-03 |
Phoenix Biosciences |
Treatments for viral infections
|
KR100392292B1
(ko)
|
2000-01-07 |
2003-07-22 |
주식회사 펩트론 |
5원환 융합 방향족 헤테로사이클릭 화합물을 유효성분으로 하는 hcv 치료제 조성물
|
US6727267B2
(en)
|
2000-04-05 |
2004-04-27 |
Tularik Inc. |
NS5B HVC polymerase inhibitors
|
WO2001077371A1
(fr)
|
2000-04-07 |
2001-10-18 |
Shionogi & Co., Ltd. |
Procede de dosage de preincubation
|
ES2312436T3
(es)
|
2000-04-18 |
2009-03-01 |
Virco Bvba |
Metodos para medir la resitencia a los farmacos.
|
US6415797B1
(en)
|
2000-07-07 |
2002-07-09 |
First Circle Medical, Inc. |
Treatment of human herpesviruses using hyperthermia
|
MXPA03000627A
(es)
|
2000-07-21 |
2004-07-30 |
Schering Corp |
Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
|
US7244721B2
(en)
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
KR20030043924A
(ko)
|
2000-08-02 |
2003-06-02 |
오르토-맥네일 파마슈티칼, 인코퍼레이티드 |
에리트로포이에틴 투여에 의한 개선된 항-바이러스 및항-종양 화학 요법
|
SV2003000617A
(es)
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
WO2002030455A2
(de)
|
2000-10-12 |
2002-04-18 |
Viromics Gmbh |
Mittel zur behandlung von virus-infektionen
|
EP1363703A4
(en)
|
2000-10-13 |
2006-06-07 |
Univ Monash |
PREVENTION OF DISEASES BY REACTIVATION OF THYMUS
|
CN1516599A
(zh)
|
2000-10-18 |
2004-07-28 |
���鹫˾ |
病毒唑-聚乙二醇化干扰素α联合治疗慢性传染性丙型肝炎的方法
|
FR2815543B1
(fr)
|
2000-10-19 |
2003-10-24 |
Sedat |
Seringue d'auto-injection d'un melange extemporane
|
DE60135481D1
(de)
|
2000-10-20 |
2008-10-02 |
Genetics Inst |
Verwendung von il-13 inhibitoren zur behandlung von tumoren
|
EP1337504A4
(en)
|
2000-11-08 |
2005-10-05 |
Cellgate Inc |
NOVEL AMINO ACID CONJUGATES AND POLYAMINE ANALOGUES USEFUL AS ANTICANCING AGENTS
|
WO2002053096A2
(en)
|
2000-12-06 |
2002-07-11 |
The Trustees Of The University Of Pennsylvania |
Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins
|
US6777395B2
(en)
|
2001-01-22 |
2004-08-17 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
CN1245215C
(zh)
|
2001-02-28 |
2006-03-15 |
四川省生物工程研究中心 |
重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
|
GB0107924D0
(en)
|
2001-03-29 |
2001-05-23 |
Angeletti P Ist Richerche Bio |
Inhibitor of hepatitis C virus NS3 protease
|
US6673775B2
(en)
|
2001-04-18 |
2004-01-06 |
Schering Corporation |
Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
|
WO2002089731A2
(en)
|
2001-05-03 |
2002-11-14 |
Stanford University |
Agents for treatment of hcv and methods of use
|
US6833351B2
(en)
|
2001-05-21 |
2004-12-21 |
Douglas T. Dieterich |
Method of treating anemia caused by ribavirin treatment of hepatitis C using erythropoietin alpha
|
US20030138403A1
(en)
|
2001-06-29 |
2003-07-24 |
Maxygen Aps |
Interferon formulations
|
WO2003002152A2
(en)
|
2001-06-29 |
2003-01-09 |
Maxygen Aps |
Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
|
BR0211336A
(pt)
|
2001-07-20 |
2004-09-28 |
Intermune Inc |
Métodos para o tratamento da fibrose do fìgado
|
WO2003024461A1
(en)
|
2001-09-20 |
2003-03-27 |
Schering Corporation |
Hcv combination therapy
|
PL369129A1
(en)
|
2001-09-28 |
2005-04-18 |
Intermune, Inc. |
Method for treating hepatitis c virus infection in treatment failure patients
|
IL160882A0
(en)
|
2001-09-28 |
2004-08-31 |
Intermune Inc |
Method for treating hepatitis c virus infection in treatment failure patients
|
HUP0401818A2
(hu)
|
2001-10-05 |
2004-11-29 |
Intermune, Inc. |
Eljárás hepatitis vírusfertőzés kezelésére multifázisos interferon felszabadulású profillal
|
WO2003037908A1
(en)
|
2001-10-31 |
2003-05-08 |
Ribapharm Inc. |
Antiviral combination therapy and compositions
|
AR037131A1
(es)
|
2001-10-31 |
2004-10-20 |
Schering Corp |
Formulaciones de jarabe de ribavirina
|
US20030153073A1
(en)
|
2001-11-07 |
2003-08-14 |
Paul Rogers |
Expansion of T cells in vitro and expanded T cell populations
|
AUPR879601A0
(en)
|
2001-11-09 |
2001-12-06 |
Biota Scientific Management Pty Ltd |
Novel chemical compounds and their use
|
US20050095224A1
(en)
|
2001-12-07 |
2005-05-05 |
Ramachandran Radhakrishnan |
Compositions and method for treating hepatitis virus infection
|
DE60221627D1
(de)
|
2001-12-21 |
2007-09-20 |
Virochem Pharma Inc |
Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
|
US6906190B2
(en)
|
2002-01-04 |
2005-06-14 |
Ribapharm Inc. |
Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
|
RU2212248C1
(ru)
|
2002-01-21 |
2003-09-20 |
Государственное образовательное учреждение высшего профессионального образования Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова |
Способ лечения больных хроническим вирусным гепатитом c
|
CA2476896A1
(en)
|
2002-02-26 |
2003-09-04 |
North Shore-Long Island Jewish Research Institute |
Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
|
CA2383243A1
(en)
|
2002-04-23 |
2003-10-23 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Method for inhibiting fibrogenesis
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2003249659A1
(en)
|
2002-05-31 |
2003-12-19 |
Schering Corporation |
Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
|
TWI334785B
(en)
|
2002-06-03 |
2010-12-21 |
Serono Lab |
Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
ATE481985T1
(de)
|
2002-07-03 |
2010-10-15 |
Ono Pharmaceutical Co |
Immunpotenzierende zusammensetzungen
|
ITMI20021860A1
(it)
|
2002-08-28 |
2004-02-29 |
Scalia Antonio Cassar |
Impiego dei triptani come agenti antivirali.
|
EP1556498A1
(en)
|
2002-11-01 |
2005-07-27 |
Cadila Healthcare Ltd. |
Method for producing recombinant human interferon alpha 2b polypeptide in pichia pastoris
|
WO2004043435A2
(en)
|
2002-11-13 |
2004-05-27 |
Control Delivery Systems, Inc. |
Systemic delivery of antiviral agents
|
AU2003295773A1
(en)
|
2002-11-21 |
2004-06-18 |
Novacea, Inc. |
Treatment of liver disease with active vitamin d compounds
|
WO2004073599A2
(en)
|
2003-02-18 |
2004-09-02 |
Pfizer Inc. |
Inhibitors of hepatitis c virus, compositions and treatments using the same
|
US20070077225A1
(en)
|
2003-02-28 |
2007-04-05 |
Blatt Lawrence M |
Continuous delivery methods for treating hepatitis virus infection
|
EP1601368A2
(en)
|
2003-02-28 |
2005-12-07 |
Intermune, Inc. |
Methods and compositions for treatment of viral diseases
|
AU2003225670A1
(en)
|
2003-02-28 |
2004-09-28 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
TWI269656B
(en)
|
2003-03-05 |
2007-01-01 |
Original Image Co Ltd |
Therapeutical composition for hepatitis C
|
UA64191A
(en)
|
2003-03-14 |
2004-02-16 |
Yevhenii Mykhailovych Neiko |
Method for treating chronic hepatitises of various etiology
|
US20040198840A1
(en)
|
2003-04-02 |
2004-10-07 |
Deloach Reuben Edwin |
Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation
|
ATE422895T1
(de)
|
2003-04-16 |
2009-03-15 |
Bristol Myers Squibb Co |
Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
|
US20040258663A1
(en)
|
2003-05-08 |
2004-12-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of interferon alpha
|
WO2005000308A2
(en)
|
2003-05-15 |
2005-01-06 |
Rigel Pharmaceuticals, Inc. |
Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
|
MY143076A
(en)
|
2003-05-21 |
2011-02-28 |
Boehringer Ingelheim Int |
Hepatitis c inhibitors compounds
|
ES2726998T3
(es)
|
2003-05-30 |
2019-10-11 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
US20050187170A1
(en)
|
2003-06-16 |
2005-08-25 |
Biocryst Pharmaceuticals, Inc. |
Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
|
EP1643981A2
(en)
|
2003-06-20 |
2006-04-12 |
Viral Genomix, Inc. |
Antiviral compositions and methods of using the same
|
AU2004260009A1
(en)
|
2003-07-11 |
2005-02-03 |
Oregon Health And Science University |
Methods of treatment and disgnosis using modulators of virus-induced cellular gene sequences
|
MD2549G2
(ro)
|
2003-07-18 |
2005-08-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament a hepatitei virale cronice C.
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
WO2005018330A1
(en)
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
NZ545536A
(en)
|
2003-09-05 |
2010-04-30 |
Anadys Pharmaceuticals Inc |
TLR7 ligands for the treatment of hepatitis C
|
WO2005023289A1
(ja)
|
2003-09-08 |
2005-03-17 |
Intellectual Property Consulting Incorporated |
慢性c型肝炎を治療するための医薬組成物
|
AR045870A1
(es)
|
2003-10-11 |
2005-11-16 |
Vertex Pharma |
Terapia de combinacion para la infeccion de virus de hepatitis c
|
US7491794B2
(en)
|
2003-10-14 |
2009-02-17 |
Intermune, Inc. |
Macrocyclic compounds as inhibitors of viral replication
|
AU2004281780B2
(en)
|
2003-10-14 |
2009-03-19 |
F. Hoffmann-La Roche Ltd |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication
|
WO2005038056A1
(en)
|
2003-10-14 |
2005-04-28 |
Intermune, Inc. |
Combination therapy for the treatment of viral diseases
|
US20050085528A1
(en)
|
2003-10-17 |
2005-04-21 |
Pfizer Inc. |
Parmaceutical
|
PL1692516T3
(pl)
|
2003-10-24 |
2011-05-31 |
Immunaid Pty Ltd |
Sposób terapii
|
PT1677827E
(pt)
|
2003-10-27 |
2009-03-13 |
Vertex Pharma |
Associações para o tratamento do vhc
|
WO2005043118A2
(en)
|
2003-10-27 |
2005-05-12 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
UA68233A
(en)
|
2003-11-25 |
2004-07-15 |
Univ Zaporizhia State Medical |
Method for treating chronic hepatitis c
|
US7078064B2
(en)
|
2003-12-03 |
2006-07-18 |
George Zabrecky |
Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
|
SI2161273T1
(sl)
|
2003-12-22 |
2015-10-30 |
K.U.Leuven Research & Development |
Imidazo(4,5-c)piridin spojine in postopki protivirusnega zdravljenja
|
WO2005067454A2
(en)
|
2003-12-23 |
2005-07-28 |
Valeant Pharmaceuticals North America |
Combination therapy for treating hepatitis c virus infection
|
WO2005062949A2
(en)
|
2003-12-23 |
2005-07-14 |
Intermune, Inc. |
Method for treating hepatitis virus infection
|
WO2005067963A1
(en)
|
2003-12-23 |
2005-07-28 |
Intermune, Inc. |
Use of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimens
|
DE10361944A1
(de)
|
2003-12-31 |
2005-07-28 |
Viromics Gmbh |
Mittel zur Hemmung der Virusreplikation durch Regulation der Proteinfaltung
|
US20080234182A1
(en)
|
2007-03-22 |
2008-09-25 |
Innovative Biologics, Inc. |
Blockers of pore-forming virulence factors and their use as anti-infectives
|
EP1718315A4
(en)
|
2004-02-06 |
2008-08-13 |
Univ Monash |
HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS
|
US7205330B2
(en)
|
2004-02-27 |
2007-04-17 |
Schering Corporation |
Inhibitors of hepatitis C virus NS3 protease
|
AR048832A1
(es)
|
2004-04-22 |
2006-05-31 |
Smith Howard J & Ass Pty Ltd |
Tratamiento de soporte de enfermedades hepaticas
|
PL1747023T5
(pl)
|
2004-05-04 |
2017-05-31 |
Univ Leland Stanford Junior |
Sposób i kompozycje do zmniejszania ilości genomu wirusowego HCV w komórkach docelowych
|
AR049635A1
(es)
|
2004-05-06 |
2006-08-23 |
Schering Corp |
(1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
|
JP2008505059A
(ja)
|
2004-05-06 |
2008-02-21 |
コンジュシェム バイオテクノロジーズ インコーポレイティド |
特異的ウイルス標的用化合物
|
WO2006016930A2
(en)
|
2004-05-14 |
2006-02-16 |
Intermune, Inc. |
Methods for treating hcv infection
|
EP1753775B1
(en)
|
2004-05-25 |
2012-12-26 |
Boehringer Ingelheim International GmbH |
Process for preparing acyclic hcv protease inhibitors
|
CN102512372A
(zh)
|
2004-06-08 |
2012-06-27 |
沃泰克斯药物股份有限公司 |
药物组合物
|
AU2005261868B2
(en)
|
2004-07-14 |
2009-01-15 |
Novartis Ag |
Use of a combination of cyclosporine and pegylated interferon for treating hepatitis C (HCV)
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
EP1627641A1
(en)
|
2004-08-04 |
2006-02-22 |
Victor Eluwa |
Pharmaceutical compositions comprising metal oxides and uses thereof
|
US7153848B2
(en)
|
2004-08-09 |
2006-12-26 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
US7348425B2
(en)
|
2004-08-09 |
2008-03-25 |
Bristol-Myers Squibb Company |
Inhibitors of HCV replication
|
CA2581930A1
(en)
|
2004-09-27 |
2006-04-06 |
Jane Trepel |
Modulating mxa expression
|
BRPI0516825A
(pt)
|
2004-10-01 |
2008-09-23 |
Vertex Pharma |
inibição da protease ns3-ns4a do vìrus da hepatite c (vhc)
|
UA88484C2
(ru)
|
2004-10-01 |
2009-10-26 |
Дебиофарм Са |
ПРИМЕНЕНИЕ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИНА ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИИ ГЕПАТИТА С И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ВКЛЮЧАЕТ [D-MeAla]3-[EtVal]4-ЦИКЛОСПОРИН
|
US7723310B2
(en)
|
2004-10-18 |
2010-05-25 |
Three Rivers Pharmaceuticals, Llc |
Large dose ribavirin formulations
|
US20060228333A1
(en)
|
2004-10-20 |
2006-10-12 |
Kye-Hyung Paik |
Methods for control of tumors and chronic infections by modulating immunologically informed carriers homing to tolerogenic organs or tissues
|
WO2006043153A2
(en)
|
2004-10-20 |
2006-04-27 |
Michel Xilinas |
Use of zinc and copper chelators for the treatment of viral diseases
|
JP2008517986A
(ja)
|
2004-10-26 |
2008-05-29 |
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー |
抗ウイルス薬としての四環式インドール誘導体
|
TWI437990B
(zh)
|
2004-10-29 |
2014-05-21 |
Vertex Pharma |
Vx-950之醫藥用途
|
US7592315B2
(en)
|
2004-11-02 |
2009-09-22 |
Schering Corporation |
Peptide viral entry inhibitors
|
WO2006055711A1
(en)
|
2004-11-18 |
2006-05-26 |
Kent Hann |
Compositions containing aloe vera isolate and a prebiotic and their therapeutic application
|
JP2008523082A
(ja)
|
2004-12-09 |
2008-07-03 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
抗菌活性および抗癌活性を有するヌクレオチド
|
TW200633718A
(en)
|
2004-12-16 |
2006-10-01 |
Applied Research Systems |
Treatment of hepatitis c in the asian population
|
DE102004061746A1
(de)
|
2004-12-22 |
2006-07-06 |
Bayer Healthcare Ag |
Alkinyl-substituierte Thiophene
|
EP1674104A1
(en)
|
2004-12-24 |
2006-06-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV
|
EP1679065A1
(en)
|
2005-01-07 |
2006-07-12 |
OctoPlus Sciences B.V. |
Controlled release compositions for interferon based on PEGT/PBT block copolymers
|
US20080161232A1
(en)
|
2005-01-17 |
2008-07-03 |
Jerini Ag |
C5a Receptor Antagonist
|
EP2361630A1
(en)
|
2005-02-03 |
2011-08-31 |
Intarcia Therapeutics, Inc |
Implantable drug delivery device comprising particles and an osmotic pump
|
US20060194835A1
(en)
|
2005-02-09 |
2006-08-31 |
Migenix Inc. |
Compositions and methods for treating or preventing flaviviridae infections
|
WO2006089113A2
(en)
|
2005-02-18 |
2006-08-24 |
Intermune, Inc. |
Biomarkers for predicting liver fibrosis treatment efficacy
|
US8232240B2
(en)
|
2005-02-23 |
2012-07-31 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of enveloped virus infectivity
|
US20090156545A1
(en)
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
US20060229293A1
(en)
|
2005-04-06 |
2006-10-12 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
|
JP2008538354A
(ja)
|
2005-04-08 |
2008-10-23 |
キメリクス,インコーポレイテッド |
ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
|
WO2006113431A2
(en)
|
2005-04-13 |
2006-10-26 |
University Of Massachusetts |
Dual functional oligonucleotides for use as anti-viral agents
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
KR20080016597A
(ko)
|
2005-05-13 |
2008-02-21 |
바이로켐 파마 인코포레이티드 |
플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
|
WO2006127289A1
(en)
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Treatment of hcv with subtherapeutic doses of ribavirin
|
WO2006127482A1
(en)
|
2005-05-20 |
2006-11-30 |
Bioenvision, Inc. |
Methylene blue therapy of viral disease
|
CN101184771A
(zh)
|
2005-05-26 |
2008-05-21 |
先灵公司 |
干扰素-IgG融合体
|
AU2006252718B2
(en)
|
2005-05-31 |
2010-04-15 |
Novartis Ag |
Treatment of liver diseases in which iron plays a role in pathogenesis
|
US7793040B2
(en)
|
2005-06-01 |
2010-09-07 |
Microsoft Corporation |
Content addressable memory architecture
|
US20060275366A1
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Controlled-release formulation
|
US20060276404A1
(en)
|
2005-06-02 |
2006-12-07 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
US20070021351A1
(en)
|
2005-06-02 |
2007-01-25 |
Schering Corporation |
Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
|
US20060281689A1
(en)
|
2005-06-02 |
2006-12-14 |
Schering Corporation |
Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
|
US20070207949A1
(en)
|
2005-06-02 |
2007-09-06 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
WO2006130554A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
WO2006130688A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Compounds for inhibiting cathepsin activity
|
WO2006130553A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Hcv protease inhibitors
|
US20070232527A1
(en)
|
2005-06-02 |
2007-10-04 |
Anima Ghosal |
Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
|
AR055198A1
(es)
|
2005-06-02 |
2007-08-08 |
Schering Corp |
Formulaciones farmaceuticas y metodos de tratamiento que las utilizan
|
US20070237818A1
(en)
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
WO2006130552A2
(en)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Methods of treating hepatitis c virus
|
PL1891089T3
(pl)
|
2005-06-02 |
2015-05-29 |
Merck Sharp & Dohme |
Inhibitory proteazy HCV w połączeniu z pokarmem
|
ES2392544T3
(es)
|
2005-06-07 |
2012-12-11 |
Yale University |
Métodos de tratamiento del cáncer y otras enfermedades o estados patológicos usando LFMAU y LDT
|
RU2293572C1
(ru)
|
2005-07-18 |
2007-02-20 |
Гюнтер Хаазе |
Способ лечения хронического вирусного гепатита с генотип-2 с умеренной активностью
|
AR057456A1
(es)
|
2005-07-20 |
2007-12-05 |
Merck & Co Inc |
Inhibidores de la proteasa ns3 del vhc
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
EP1910341B1
(en)
|
2005-08-02 |
2013-01-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
EP1924596A4
(en)
|
2005-08-12 |
2009-07-29 |
Human Genome Sciences Inc |
ALBUM INFUSION PROTEINS
|
DE102005038768A1
(de)
|
2005-08-16 |
2007-02-22 |
Toximed Gmbh |
Pharmazeutischer Wirkstoff gegen Borreliose
|
NZ604087A
(en)
|
2005-08-19 |
2014-07-25 |
Vertex Pharma |
Processes and intermediates for the preparation of protease inhibitors
|
WO2007030560A2
(en)
|
2005-09-08 |
2007-03-15 |
Philadelphia Health & Education Corporation, D/B/A Drexel University College Of Medicine |
Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
|
US7531164B2
(en)
|
2005-10-21 |
2009-05-12 |
Duke University |
Preventing bacterial or viral infectivity and composition containing infection preventing additive
|
IE20050723A1
(en)
|
2005-10-28 |
2007-05-30 |
Patrick T Prendergast |
Anti-mineralocorticoid therapy of infection
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
RU2306134C2
(ru)
|
2005-11-07 |
2007-09-20 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ базисного лечения хронического вирусного гепатита c
|
JP5409008B2
(ja)
|
2005-11-11 |
2014-02-05 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
C型肝炎ウイルス改変体
|
WO2007058384A1
(en)
|
2005-11-17 |
2007-05-24 |
Osaka University |
Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
|
RU2326115C2
(ru)
|
2005-11-21 |
2008-06-10 |
Ефаг АО |
Соли 1-алкиламино-1-дезоксиполиолов с 9-оксоакридин-10-уксусной кислотой, лекарственные препараты на их основе, применение, способы профилактики и лечения
|
AR057623A1
(es)
|
2005-11-28 |
2007-12-05 |
Omega Bio Pharma H K Ltd |
Materiales y metodos para el tratamiento de las infecciones virales
|
EP1968607B1
(en)
|
2005-12-02 |
2014-01-15 |
Nabil Habib Lab |
Treatment of cancer and other diseases
|
CA2632626C
(en)
|
2005-12-09 |
2011-10-11 |
F. Hoffmann-La Roche Ag |
Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
RU2306934C1
(ru)
|
2005-12-28 |
2007-09-27 |
ГОУ ВПО Омская Государственная Медицинская Академия |
Способ лечения больных хроническим вирусным гепатитом c
|
UA100840C2
(ru)
|
2006-01-09 |
2013-02-11 |
РОМАРК ЛЕБОРЕТЕРИЗ, Эл.Си. |
Композиция для лечения вирусного гепатита
|
MD20060037A
(ro)
|
2006-01-24 |
2007-07-31 |
Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова |
Metodă de tratament al hepatitei virale acute C
|
AR059430A1
(es)
|
2006-02-09 |
2008-04-09 |
Schering Corp |
Novedosas combinaciones y metodos de inhibidores del vhc
|
US20070274951A1
(en)
|
2006-02-09 |
2007-11-29 |
Xiao Tong |
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
|
EP2340836A1
(en)
|
2006-02-27 |
2011-07-06 |
Vertex Pharmceuticals Incorporated |
Co-crystals comprising VX-950 and their pharmaceutical compositions
|
CA2646229A1
(en)
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Deuterated hepatitis c protease inhibitors
|
EP2001498A4
(en)
|
2006-03-20 |
2013-01-23 |
Vertex Pharma |
PHARMACEUTICAL COMPOSITIONS
|
EA018811B1
(ru)
|
2006-03-20 |
2013-10-30 |
Вертекс Фармасьютикалз Инкорпорейтед |
Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
|
US8895531B2
(en)
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
CA2647158C
(en)
|
2006-03-23 |
2012-07-31 |
Schering Corporation |
Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
|
US8021835B2
(en)
|
2006-05-04 |
2011-09-20 |
The Rockefeller University |
HCV coreceptor and methods of use thereof
|
WO2008060695A2
(en)
|
2006-05-22 |
2008-05-22 |
The Trustees Of The University Of Pennsylvania |
Antiviral inhibition of casein kinase ii
|
DE102006026464A1
(de)
|
2006-06-01 |
2007-12-06 |
Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma |
Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
|
AU2007254827A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
AU2007256393A1
(en)
|
2006-06-04 |
2007-12-13 |
Cellartis Ab |
Novel hepatocyte-like cells and hepatoblast-like cells derived from hBS cells
|
AU2007257959A1
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
WO2007149382A2
(en)
|
2006-06-19 |
2007-12-27 |
The Cleveland Clinic Foundation |
Therapeutic compositions and methods useful in treating hepatitis
|
RU2008152171A
(ru)
|
2006-07-05 |
2010-08-10 |
Интермьюн, Инк. (Us) |
Новые ингибиторы вирусной репликации гепатита с
|
US20080081791A1
(en)
|
2006-07-06 |
2008-04-03 |
Weida Huang |
Methods of using combinations of siRNAs for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
|
TW200819460A
(en)
|
2006-07-07 |
2008-05-01 |
Gilead Sciences Inc |
Antiviral phosphinate compounds
|
PL2041156T3
(pl)
|
2006-07-13 |
2014-05-30 |
Achillion Pharmaceuticals Inc |
Peptydy 4-amino-4-oksobutanoilowe jako inhibitory replikacji wirusowej
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
US20100158862A1
(en)
|
2006-08-11 |
2010-06-24 |
Bristol-Myers Squibb Company |
Hepatitis C Virus Inhibitors
|
US8329159B2
(en)
|
2006-08-11 |
2012-12-11 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2008022006A2
(en)
|
2006-08-11 |
2008-02-21 |
Enanta Pharmaceuticals, Inc. |
Arylalkoxyl hepatitis c virus protease inhibitors
|
WO2008063727A2
(en)
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
US7655419B2
(en)
|
2006-08-25 |
2010-02-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for identifying anti-HCV agents
|
BRPI0715714A2
(pt)
|
2006-08-25 |
2014-03-11 |
Wyeth Corp |
Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente
|
TW200815384A
(en)
|
2006-08-25 |
2008-04-01 |
Viropharma Inc |
Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
|
WO2008032227A2
(en)
|
2006-09-11 |
2008-03-20 |
Biomas, Ltd. |
Topical formulations of tellurium-containing compounds
|
AU2007294805A1
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080161324A1
(en)
|
2006-09-14 |
2008-07-03 |
Johansen Lisa M |
Compositions and methods for treatment of viral diseases
|
WO2008039179A1
(en)
|
2006-09-26 |
2008-04-03 |
Addiction Research Institute, Inc. |
Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
|
BRPI0719174A2
(pt)
|
2006-10-10 |
2017-06-13 |
Hoffmann La Roche |
preparação de pirimidinas ribofuranosil nucleosídeos
|
US7777395B2
(en)
|
2006-10-12 |
2010-08-17 |
Eastman Kodak Company |
Continuous drop emitter with reduced stimulation crosstalk
|
CA2667031C
(en)
|
2006-10-27 |
2013-01-22 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
AP2579A
(en)
|
2006-11-15 |
2013-01-29 |
Virochem Pharma Inc |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
WO2008143647A2
(en)
|
2006-11-29 |
2008-11-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating viral infection
|
WO2008073282A2
(en)
|
2006-12-07 |
2008-06-19 |
Schering Corporation |
Ph sensitive matrix formulation
|
RU2336096C1
(ru)
|
2006-12-14 |
2008-10-20 |
ООО Медицинский центр "Столица" |
Способ лечения гепатита с
|
RU2345787C2
(ru)
|
2006-12-25 |
2009-02-10 |
Государственное образовательное учреждение высшего профессионального образования "Самарский Государственный медицинский университет" |
Способ лечения хронического вирусного гепатита с
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
KR20090101372A
(ko)
|
2007-01-08 |
2009-09-25 |
페노믹스 코포레이션 |
매크로시클릭 c형 간염 프로테아제 억제제
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
US7645732B2
(en)
|
2007-01-24 |
2010-01-12 |
Board Of Regents, The University Of Texas System |
Treating hepatitis C virus infection
|
PT2118098E
(pt)
|
2007-02-01 |
2014-12-09 |
Janssen R & D Ireland |
Formas polimórficas de um inibidor macrocíclico do hcv
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
NZ579785A
(en)
|
2007-02-21 |
2012-06-29 |
Allaccem Inc |
Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
|
AP2009004960A0
(en)
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
WO2008106167A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
MD3477G2
(ro)
|
2007-03-21 |
2008-08-31 |
Николае БОДРУГ |
Metodă de tratament al hepatitei virale cronice C
|
EP2308514B1
(en)
|
2007-03-23 |
2013-06-05 |
to-BBB Holding B.V. |
Conjugates for targeted drug delivery across the blood-brain barrier
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
WO2008124384A2
(en)
|
2007-04-03 |
2008-10-16 |
Aegerion Pharmaceuticals, Inc. |
Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
|
JP2010525063A
(ja)
|
2007-04-27 |
2010-07-22 |
キメリクス,インコーポレイテッド |
ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
|
US20080269205A1
(en)
|
2007-04-27 |
2008-10-30 |
Ondine International, Ltd. |
Methods to prevent vertical transmission of infectious diseases
|
WO2008137779A2
(en)
|
2007-05-03 |
2008-11-13 |
Intermune, Inc. |
Novel macrocyclic inhibitors of hepatitis c virus replication
|
CA2686051A1
(en)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Combination therapy for the treatment of hcv infection
|
CL2008001381A1
(es)
|
2007-05-10 |
2008-11-03 |
Intermune Inc Y Array Biopharma Inc |
Compuestos derivados de tripeptidos que contienen heterociclos nitrogenados; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una infeccion de hepatitis c o vih.
|
CA2688554A1
(en)
|
2007-05-21 |
2008-11-27 |
Vertex Pharmaceuticals Incorporated |
Dose forms comprising vx-950 and their dosage regimen
|
RU2348412C1
(ru)
|
2007-06-01 |
2009-03-10 |
Лариса Леонидовна Попова |
Способ профилактики рецидива хронического вирусного гепатита с после достижения вирусологической ремиссии
|
WO2008154248A1
(en)
|
2007-06-06 |
2008-12-18 |
Inova Health System |
Prognostic chronic hepatitis c biomarkers
|
JP5465666B2
(ja)
|
2007-06-29 |
2014-04-09 |
ギリアード サイエンシーズ, インコーポレイテッド |
抗ウイルス化合物
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
EP2175865A4
(en)
|
2007-07-25 |
2012-01-11 |
Biolex Therapeutics Inc |
INTERFERON DRUG PRODUCTS WITH CONTROLLED RELEASE AND TREATMENT OF HCV INFECTIONS THEREWITH
|
WO2009015389A2
(en)
|
2007-07-26 |
2009-01-29 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
EP2194976B1
(en)
|
2007-08-03 |
2015-12-09 |
Biotron Limited |
Hepatitis C antiviral compositions comprising 5-(1-methylpyrazol-4-yl)2-naphthoylguanidine and 2'-C-methyladenosine or 2'-C-methylcytidine
|
US8629171B2
(en)
|
2007-08-08 |
2014-01-14 |
Bristol-Myers Squibb Company |
Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
|
US7728027B2
(en)
|
2007-08-08 |
2010-06-01 |
Bristol-Myers Squibb Company |
Process for synthesizing compounds useful for treating hepatitis C
|
US20110166092A1
(en)
|
2007-08-20 |
2011-07-07 |
Anadys Pharmaceuticals, Inc. |
Dosing methods for treating disease
|
JP5443360B2
(ja)
|
2007-08-30 |
2014-03-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
共結晶体およびそれを含む医薬組成物
|
WO2009033183A2
(en)
|
2007-09-08 |
2009-03-12 |
University Of Florida Research Foundation |
Compounds and methods for treatment of hcv and conditions associated with cd81 binding
|
US20090076100A1
(en)
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched gsk625433
|
CA2699280A1
(en)
|
2007-09-14 |
2009-03-26 |
Schering Corporation |
Method of treating hepatitis c patients
|
EP2203431B1
(en)
|
2007-09-17 |
2011-08-10 |
Abbott Laboratories |
Anti-infective pyrimidines and uses thereof
|
KR101552474B1
(ko)
|
2007-09-17 |
2015-09-11 |
애브비 바하마스 리미티드 |
C형 간염 치료용 우라실 또는 티민 유도체
|
TW200927102A
(en)
|
2007-09-18 |
2009-07-01 |
Univ Stanford |
Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
|
US20090082414A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched viramidine
|
US20090082366A1
(en)
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched telaprevir
|
MX2010003726A
(es)
|
2007-10-03 |
2010-09-14 |
Sabell Corp |
Composiciones herbarias y metodos de tratamiento de trastornos hepaticos.
|
US20110270212A1
(en)
|
2007-10-05 |
2011-11-03 |
Medtronic, Inc. |
Pharmacokinetic control for optimized interferon delivery
|
JP2011503060A
(ja)
|
2007-11-05 |
2011-01-27 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Vx−950、peg−ifnおよびリババリンを含むhcv併用治療剤
|
ATE525070T1
(de)
|
2007-11-15 |
2011-10-15 |
Madaus Gmbh |
Silbininkomponente zur behandlung von hepatitis
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
AU2008340430B2
(en)
|
2007-12-21 |
2013-01-24 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
TWI487522B
(zh)
|
2007-12-21 |
2015-06-11 |
賽基艾維洛米斯研究股份有限公司 |
Hcv蛋白酶抑制劑及其用途(一)
|
WO2009085267A1
(en)
|
2007-12-27 |
2009-07-09 |
Epiphany Biosciences |
Antiviral compounds
|
WO2009109665A1
(en)
|
2008-03-07 |
2009-09-11 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
JP5283106B2
(ja)
|
2008-03-14 |
2013-09-04 |
国立大学法人 熊本大学 |
C型肝炎ウイルス阻害剤
|
US20100009970A1
(en)
|
2008-03-19 |
2010-01-14 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
US20110045001A1
(en)
|
2008-03-28 |
2011-02-24 |
Biontex Laboratories Gmbh |
Transfection results of non-viral gene delivery systems by influencing of the innate immune system
|
CA2720846A1
(en)
|
2008-04-15 |
2009-11-05 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
WO2009131696A1
(en)
|
2008-04-23 |
2009-10-29 |
Vertex Pharmaceuticals Incorporated |
Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
|
DE102008029669A1
(de)
|
2008-05-16 |
2009-11-19 |
Schlaak, Jörg Friedrich, Prof. Dr. med. |
Neue Therapeutika für die Hepatitis-Therapie
|
EP2318031A4
(en)
|
2008-06-03 |
2012-09-12 |
Aethlon Medical Inc |
IMPROVED METHODS AND DEVICES FOR ANTIVIRAL THERAPY
|
AU2009255994B2
(en)
|
2008-06-05 |
2014-07-17 |
Bristol-Myers Squibb Company |
Use of pegylated Type III Interferons for the treatment of hepatitis C
|
CA2728248A1
(en)
|
2008-06-10 |
2009-12-17 |
Janssen Pharmaceutica Nv |
Telaprevir dosing regimen
|
EP2349257B1
(en)
|
2008-06-17 |
2013-11-27 |
Universidade Federal de Minas Gerais-UFMG |
Use of paf receptor for treating infections caused by flaviviridae
|
CA2731177C
(en)
|
2008-07-22 |
2013-10-29 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors
|
CA2737144A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Methods for treating viral disorders
|
RU2373952C1
(ru)
|
2008-07-30 |
2009-11-27 |
Юрий Михайлович Амбалов |
Способ лечебного питания больных хроническим гепатитом с, получающих комплексную противовирусную терапию
|
WO2010017178A1
(en)
|
2008-08-06 |
2010-02-11 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of hepatitis c with immunomodulator compounds
|
CN102112442B
(zh)
|
2008-08-07 |
2014-12-10 |
弗·哈夫曼-拉罗切有限公司 |
制备大环的方法
|
JP2011530532A
(ja)
|
2008-08-07 |
2011-12-22 |
シェーリング コーポレイション |
固体分子分散物中のhcvプロテアーゼインヒビターの薬学的処方物
|
US20100092479A1
(en)
|
2008-08-18 |
2010-04-15 |
Combinatorx (Singapore) Pte. Ltd. |
Compositions and methods for treatment of viral diseases
|
WO2010020676A1
(en)
|
2008-08-20 |
2010-02-25 |
Vib Vzw |
The use of topoisomerase type i inhibitors to treat viral infections
|
JP2012501345A
(ja)
|
2008-08-28 |
2012-01-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Hcv遺伝子型の分析
|
JP5409636B2
(ja)
|
2008-08-29 |
2014-02-05 |
国立大学法人大阪大学 |
抗c型肝炎ウイルス組成物
|
EP2323622A1
(en)
|
2008-09-03 |
2011-05-25 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
UY32099A
(es)
*
|
2008-09-11 |
2010-04-30 |
Enanta Pharm Inc |
Inhibidores macrocíclicos de serina proteasas de hepatitis c
|
MY153093A
(en)
|
2008-09-16 |
2014-12-31 |
Boehringer Ingelheim Int |
Crystalline forms of a 2-thiazolyl-4-quinolinyl-oxy derivative, a potent hcv inhibitor
|
JP5539363B2
(ja)
|
2008-09-17 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ
|
WO2010031832A2
(en)
|
2008-09-18 |
2010-03-25 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc |
Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
|
JP2012503669A
(ja)
|
2008-09-24 |
2012-02-09 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
肝炎を治療するためのpeg−インターフェロン、リバビリンおよびvx−950を含む治療レジメ
|
JP2012503619A
(ja)
|
2008-09-26 |
2012-02-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Hcv感染に対する抗ウイルス治療のための標的としての宿主細胞キナーゼ
|
CA2738985A1
(en)
|
2008-09-30 |
2010-04-08 |
Mochida Pharmaceutical Co., Ltd. |
Therapeutic agent for hepatitis c
|
EP2341924A4
(en)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
METHOD FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS
|
AU2009302344A1
(en)
|
2008-10-08 |
2010-04-15 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center |
Treating Hepatitis C virus infection with over-expression of microRNA-196
|
CA2740728A1
(en)
|
2008-10-15 |
2010-04-22 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
WO2010049438A2
(en)
|
2008-10-30 |
2010-05-06 |
Innate Pharma |
Improved methods of using phosphoantigens for the treatment of diseases
|
WO2010053942A1
(en)
|
2008-11-05 |
2010-05-14 |
Vertex Pharmaceuticals Incorporated |
Methods for treating hepatitis c virus infection
|
SI2358355T1
(sl)
|
2008-11-21 |
2014-02-28 |
Boehringer Ingelheim Gmbh |
Farmacevtski sestavek potentnega inhibitorja HCV za oralno dajanje
|
CN102245599B
(zh)
|
2008-12-10 |
2014-05-14 |
艾其林医药公司 |
作为病毒复制抑制剂的新的4-氨基-4-氧代丁酰基肽
|
EP2356236B1
(en)
|
2008-12-11 |
2015-07-29 |
Xiangxue Group (Hong Kong) Company Limited |
siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION
|
WO2010069809A1
(en)
|
2008-12-18 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Biomarkers for hcv treatment response
|
CN102753563A
(zh)
|
2008-12-23 |
2012-10-24 |
吉利德制药有限责任公司 |
核苷类似物
|
WO2010076788A2
(en)
|
2008-12-29 |
2010-07-08 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
|
US8840934B2
(en)
|
2009-01-02 |
2014-09-23 |
Rainbow Pharmaceutical Sa |
Uses of ammonium chloride
|
SG172921A1
(en)
|
2009-01-09 |
2011-08-29 |
Univ Cardiff |
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
|
RU2398582C1
(ru)
|
2009-01-19 |
2010-09-10 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.М. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
Способ лечения хронического вирусного гепатита с 1-генотипа с умеренной активностью и репликативностью
|
JP2012517478A
(ja)
|
2009-02-12 |
2012-08-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、hcv組合せ治療剤
|
US8101643B2
(en)
|
2009-02-27 |
2012-01-24 |
Enanta Pharmaceuticals, Inc. |
Benzimidazole derivatives
|
AR075584A1
(es)
|
2009-02-27 |
2011-04-20 |
Intermune Inc |
COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
|
BRPI1013227A2
(pt)
|
2009-03-05 |
2016-03-29 |
Ascendis Pharma As |
pró-fármacos transportadores de interferon alfa
|
WO2010101649A2
(en)
|
2009-03-05 |
2010-09-10 |
Pablo Gastaminza |
Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
|
ES2599979T3
(es)
|
2009-04-24 |
2017-02-06 |
Roche Innovation Center Copenhagen A/S |
Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
|
ES2683736T3
(es)
|
2009-04-25 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Procedimientos para mejorar la farmacocinética
|
PL3002281T3
(pl)
|
2009-05-13 |
2018-02-28 |
Gilead Pharmasset Llc |
Związki przeciwwirusowe
|
TWI576352B
(zh)
*
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2010135649A1
(en)
|
2009-05-21 |
2010-11-25 |
Schering Corporation |
Genetic markers associated with interferon-alpha response
|
NZ591973A
(en)
*
|
2009-06-11 |
2013-03-28 |
Abbott Lab |
Anti-viral compounds to treat hcv infection
|
UY32721A
(es)
|
2009-06-23 |
2011-01-31 |
Gilead Sciences Ltd |
Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
|
UY32715A
(es)
|
2009-06-23 |
2011-01-31 |
Gilead Sciences Inc |
Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
|
WO2010151488A1
(en)
|
2009-06-23 |
2010-12-29 |
Gilead Sciences, Inc. |
Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv
|
JP5932640B2
(ja)
|
2009-06-26 |
2016-06-08 |
ロマーク ラボラトリーズ エル.シー. |
インフルエンザを治療するための化合物および方法
|
JP5607736B2
(ja)
|
2009-07-07 |
2014-10-15 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎ウイルスプロテアーゼ阻害剤のための医薬組成物
|
RU2400229C1
(ru)
|
2009-07-13 |
2010-09-27 |
Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная медицинская академия им. И.И. Мечникова Федерального агентства по здравоохранению и социальному развитию" |
СПОСОБ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С, ГЕНОТИПОМ 3а
|
US20110020272A1
(en)
|
2009-07-24 |
2011-01-27 |
Ulrich Schubert |
Combination therapy for treating hepatitis viral infection
|
JP2013500713A
(ja)
|
2009-07-31 |
2013-01-10 |
サントル オスピタリエ ウニヴェルシテール ヴォドア |
Hcv感染患者においてc型肝炎の転帰を診断又は予測する方法
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
CN102470158A
(zh)
|
2009-08-27 |
2012-05-23 |
默沙东公司 |
制备丙型肝炎病毒的蛋白酶抑制剂的工艺方法
|
WO2011038224A1
(en)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Methods for treating viral disorders
|
WO2011041551A1
(en)
|
2009-10-01 |
2011-04-07 |
Intermune, Inc. |
Therapeutic antiviral peptides
|
US8415374B2
(en)
*
|
2009-10-12 |
2013-04-09 |
Bristol-Myers Squibb Company |
Combinations of hepatitis C virus inhibitors
|
WO2011056650A2
(en)
|
2009-10-27 |
2011-05-12 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
US9174988B2
(en)
|
2009-10-27 |
2015-11-03 |
Trustees Of Boston University |
Small molecule inhibitors of hepatitis C virus
|
MX2012004971A
(es)
|
2009-10-30 |
2012-06-12 |
Boehringer Ingelheim Int |
Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
|
JP2013511259A
(ja)
|
2009-11-09 |
2013-04-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
リバビリン誘発性貧血と関連しているマーカー
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
US8623416B2
(en)
|
2009-11-25 |
2014-01-07 |
Michael Zasloff |
Formulations comprising aminosterols
|
AU2010333656B2
(en)
|
2009-12-18 |
2015-08-27 |
Boehringer Ingelheim International Gmbh |
HCV combination therapy
|
WO2011079016A1
(en)
|
2009-12-22 |
2011-06-30 |
Gilead Sciences, Inc. |
Methods of treating hbv and hcv infection
|
CA2785492C
(en)
|
2009-12-23 |
2018-07-24 |
Novartis Ag |
Lipids, lipid compositions, and methods of using them
|
RU2424794C1
(ru)
|
2009-12-30 |
2011-07-27 |
Государственное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО УГМА Росздрава) |
Способ лечения врожденного гепатита с у детей первого года жизни
|
WO2011094489A1
(en)
|
2010-01-29 |
2011-08-04 |
Vertex Pharmaceuticals Incorporated |
Therapies for treating hepatitis c virus infection
|
NZ602288A
(en)
|
2010-03-10 |
2014-02-28 |
Abbvie Bahamas Ltd |
Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
|
US8530497B2
(en)
|
2010-03-11 |
2013-09-10 |
Boehringer Ingelheim International Gmbh |
Crystalline salts of a potent HCV inhibitor
|
CN102858790A
(zh)
*
|
2010-03-31 |
2013-01-02 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
TW201211047A
(en)
*
|
2010-06-10 |
2012-03-16 |
Gilead Sciences Inc |
Methods for treating HCV
|
NZ605440A
(en)
|
2010-06-10 |
2014-05-30 |
Abbvie Bahamas Ltd |
Solid compositions comprising an hcv inhibitor
|
CA2745102A1
(en)
|
2010-06-29 |
2011-12-29 |
Medicorp Institute Of Canada |
Pharmaceutical composition and method of use to improve organ function
|
RU2429877C1
(ru)
|
2010-06-30 |
2011-09-27 |
Общество с ограниченной ответственностью "ИНГИЛС" |
Способ лечения хронического вирусного гепатита с
|
EP2593105A1
(en)
|
2010-07-14 |
2013-05-22 |
Vertex Pharmaceuticals Incorporated |
Palatable pharmaceutical composition comprising vx-950
|
WO2012015712A1
(en)
|
2010-07-30 |
2012-02-02 |
Schering Corporation |
Inhibition of cyp3a drug metabolism
|
US20120196272A1
(en)
|
2010-08-05 |
2012-08-02 |
Roche Molecular Systems, Inc. |
Prediction of HCV Viral Kinetics in Interferon-Free Treatment
|
US20120196794A1
(en)
|
2010-08-06 |
2012-08-02 |
Bristol-Myers Squibb Company |
Combinations of Hepatitis C Virus Inhibitors
|
PE20171640A1
(es)
|
2010-09-22 |
2017-11-09 |
Alios Biopharma Inc |
Analogos de nucleotidos sustituidos
|
KR20130120469A
(ko)
|
2010-09-29 |
2013-11-04 |
머크 샤프 앤드 돔 코포레이션 |
폴리시클릭 헤테로사이클 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
|
MX2013003060A
(es)
*
|
2010-09-30 |
2013-05-30 |
Boehringer Ingelheim Int |
Terapia de combinacion para tratar infeccion por hcv.
|
US20120107278A1
(en)
|
2010-10-29 |
2012-05-03 |
Pharmasset, Inc. |
Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype
|
US20130273005A1
(en)
|
2010-12-20 |
2013-10-17 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
WO2012139028A2
(en)
|
2011-04-06 |
2012-10-11 |
The Trustees Of Princeton University |
Anti-viral combination therapy
|
EP2723863A1
(en)
|
2011-06-23 |
2014-04-30 |
Stella ApS |
Hcv combination therapy
|
EP2726610A1
(en)
|
2011-06-30 |
2014-05-07 |
Stella ApS |
Hcv combination therapy
|
EP2726611A1
(en)
|
2011-06-30 |
2014-05-07 |
Stella ApS |
Hcv combination therapy
|
WO2013025975A1
(en)
|
2011-08-17 |
2013-02-21 |
Glaxosmithkline Llc |
Combination treatments for hepatitis c
|
WO2013024155A1
(en)
|
2011-08-17 |
2013-02-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
|
WO2013024158A1
(en)
|
2011-08-17 |
2013-02-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
|
SG2014010490A
(en)
|
2011-08-24 |
2014-04-28 |
Glaxosmithkline Llc |
Combination treatments for hepatitis c
|
US20130072528A1
(en)
|
2011-09-16 |
2013-03-21 |
Abbvie Inc. |
Methods for Treating HCV
|
EP2709613B2
(en)
|
2011-09-16 |
2020-08-12 |
Gilead Pharmasset LLC |
Methods for treating hcv
|
US8466159B2
(en)
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
AU2013201532B2
(en)
|
2011-10-21 |
2014-10-02 |
Abbvie Ireland Unlimited Company |
Methods for treating HCV
|
SE1450130A1
(sv)
|
2011-10-21 |
2014-05-07 |
Abbvie Inc |
Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
|
US8492386B2
(en)
|
2011-10-21 |
2013-07-23 |
Abbvie Inc. |
Methods for treating HCV
|
BR112014010545A2
(pt)
|
2011-10-31 |
2017-05-02 |
Merk Sharp & Dohme Corp |
composição farmacêutica, método para tratar um paciente infectado com vírus da hepatite c, uso de uma composição
|
US20130137084A1
(en)
|
2011-11-28 |
2013-05-30 |
Roche Molecular Systems, Inc. |
Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses
|
WO2013096680A1
(en)
|
2011-12-22 |
2013-06-27 |
Alios Biopharma, Inc. |
Substituted phosphorothioate nucleotide analogs
|